Marinobufagenin in essential hypertension and primary aldosteronism: a cardiotonic steroid with clinical and diagnostic implications
Authors:
- Grzegorz PiechaGPGrzegorz Piecha
- Eberhard RitzEREberhard Ritz
- Andreas MeinitzerAMAndreas Meinitzer
- Josef HaasJHJosef Haas
- Burkert PieskeBPBurkert Pieske
- Andrzej WiecekAWAndrzej Wiecek
- Jutta Rus-MachanJRJutta Rus-Machan
- Hermann ToplakHTHermann Toplak
- Winfried MärzWMWinfried März
- Nicolas VerheyenNVNicolas Verheyen
- Martin GakschMGMartin Gaksch
- 30 April 2014
- journal article
- research article
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 37 (2) , 108-115
Abstract
The cardiotonic steroid marinobufagenin (MBG) is increasingly suggested to be responsible for some of the cardiovascular injury that has been previously attributed to aldosterone. We examined the clinical correlates of circulating MBG concentrations in hypertensive patients and tested the hypothesis that MBG serves as a reliable diagnostic tool for detecting primary aldosteronism (PA). Plasma MBG concentrations (mean: 0.51±0.25 nmol/l) were measured in the morning fasting samples in 20 patients with PA and 20 essential hypertensive (EH) controls matched for age, sex, body mass index, renal function, urinary sodium and intake of antihypertensive medication (mean age: 51.6 years; 52.2% women). Overall, plasma MBG was directly correlated with plasma aldosterone, aldosterone to active renin ratio (AARR), diastolic blood pressure, mean carotid intima-media thickness, serum sodium, urinary protein to creatinine ratio and inversely with serum potassium levels. Plasma MBG levels were significantly higher in patients with PA compared to EH (mean: 0.68±0.12 versus 0.35±0.24 nmol/l; p0.49 nmol/l with specificity and sensitivity values of 0.85 and 0.95, respectively, which were higher than those at the optimum AARR cut-off at >3.32 ng/dl/µU/ml. In a well-characterized cohort, values of plasma MBG were significantly related to clinical correlates of cardiovascular and renal disease. Plasma MBG emerged as a valuable alternative to the AARR for screening of PA.Keywords
This publication has 41 references indexed in Scilit:
- Circulating aldosterone and mortality in female nursing home residentsExperimental Gerontology, 2013
- Screening for Adrenal-Endocrine Hypertension: Overview of Accuracy and Cost-effectivenessEndocrinology and Metabolism Clinics of North America, 2011
- Endogenous cardiotonic steroids in chronic renal failureNephrology Dialysis Transplantation, 2011
- Endogenous cardiotonic steroids and salt-sensitive hypertensionBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- Spironolactone Attenuates Experimental Uremic Cardiomyopathy by Antagonizing MarinobufageninHypertension, 2009
- Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronismBMC Endocrine Disorders, 2009
- Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic TargetsPharmacological Reviews, 2009
- Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertensionJournal Of Hypertension, 2008
- Endogenous sodium pump inhibitors and age-associated increases in salt sensitivity of blood pressure in normotensivesAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2008
- Effect of endogenous digoxin-like factor and digoxin antibody on myocardial Na+, K+-pump activity and ventricular arrhythmias in acute myocardial ischaemia in ratsCardiovascular Research, 1993